Tag: licensing
-
Personal Leukemia Immunotherapy Given Breakthrough Status
7 July 2014. The U.S. Food and Drug Administration designated as a breakthrough a personalized immunotherapy developed by University of Pennsylvania in Philadelphia to treat acute lymphoblastic leukemia that does not respond to other treatments or has relapsed. FDA assigns a breakthrough designation and accelerates review of drugs or biologic therapies that treat a serious…
-
University Offers Tuberculosis Drug Technology for Licensing
2 July 2014. A new process for developing drugs for tuberculosis designed at ETH Zurich, the Swiss Federal Institute of Technology, is offered for licensing by the university to companies for commercialization. The technology that aims to overcome resistance to many current tuberculosis drugs is the result of research from the lab of Zurich pharmaceutical…
-
Spin-Off Licenses Genomic Technology from Wash. University
30 June 2014. PierianDx, a new company formed by medical faculty and practitioners at Washington University in St. Louis, licensed genomic technology from the university to commercialize diagnostic tools for personalized medicine. Financial details of the licensing deal were not disclosed. The start-up company plans to offer the technology in a system developed internally by…
-
Late Trial Testing Topical Gel for Diabetic Nerve Pain
26 June 2014. A late-stage clinical trial testing a topical gel to treat diabetic nerve pain completed its enrollment, according to BioDelivery Sciences International in Raleigh, North Carolina, the study’s sponsor. The trial is the first of two clinical studies of Clonidine Topical Gel in preparation for the company’s new drug application with the U.S.…
-
Fibrocell Science Licenses Stem Cell Technology from UCLA
17 June 2014. The biotechnology company Fibrocell Science Inc. in Exton, Pennsylvania is licensing stem cell discoveries from University of California in Los Angeles for personalized treatments of serious bone and connective tissue conditions. Financial aspects of the licensing deal were not disclosed. Fibrocell Science develops treatments for rare and serious conditions affecting bones, connective…
-
FDA Grants Experimental Leukemia Drug Orphan Status
16 June 2014. Agios Pharmaceuticals Inc. in Cambridge, Massachusetts says the U.S. Food and Drug Administration designated its therapy for acute myelogenous leukemia an orphan drug, qualifying it for tax incentives and other benefits. The orphan drug status comes at the same time of new findings reported from an early clinical trial of the drug,…
-
New Company Formed to Commercialize Synthetic DNA Discovery
7 May 2014. Synthorx Inc., a spin-off company from Scripps Research Institute in La Jolla, California, will commercialize research licensed from Scripps that adds synthetic DNA elements into natural DNA of organisms. The research, led by Scripps chemistry professor and Synthorx co-founder Floyd Romesberg, appears today online in the journal Nature (paid subscription required). Romesberg,…
-
Regeneron, Avalanche to Partner on Eye Disorder Gene Therapy
5 May 2014. Regeneron Pharmaceuticals in Tarrytown, New York is licensing gene therapy technology from Avalanche Biotechnologies in Menlo Park, California to develop and commercialize new treatments for eye diseases. The value of the deal is at least $640 million, but not all payment amounts were disclosed. Regeneron is a biopharmaceutical company developing therapies for inflammation, cardiovascular and metabolic disorders, cancer,…
-
NYU Medical Center Starts Drug Discovery Partnership Program
1 May 2014. New York University’s Langone Medical Center unveiled an initiative to establish more partnerships with drug and biotechnology companies that move initial therapeutic targets into active drug development programs. NYU’s Office of Therapeutics Alliances, says the university, aims to fill the translation gap or “valley of death” between research performed by academic scientists…
-
Diagnostics Firm Licenses Severe Food Allergy Gene Research
28 April 2014. Diagnovus LLC, a molecular diagnostics developer in Nashville, is licensing research on food allergies to detect a severe type of allergic condition based on a patient’s genetics. Financial terms of the deal with Cincinnati Children’s Hospital Medical Center that conducted the research were not disclosed. The test will analyze a patient’s genome…